Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a nasal spray vaccine stop croup in kids?

NCT ID NCT00186927

Vaccine Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental nasal vaccine made from a harmless virus (Sendai virus) that is similar to the one causing croup. The goal is to see if it is safe and helps children ages 1 to 5 build protection against croup. About 54 children will receive the vaccine as nose drops and be monitored for side effects and immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2005

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 months to 6 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria; * Parent or legal guardian willing and able to give informed consent and comply with study requirements * Child is greater than or equal to one year of age and less than six years of age * Adequate blood, liver and kidney function * Has not or will not receive other vaccinations within 30 days of receiving study vaccine Exclusion Criteria: * History of allergy to eggs or gentamicin * History of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition * Children who have a family history of primary immunodeficiency or lack history of maternal or paternal immune status * Height or weight less than 5th percentile * Upper respiratory tract infection (URI) or household member with URI * Evidence of developmental delay or evolving neurological disorders * Household member or daycare contact (i.e. stay in the same room in daycare) less than 24 months of age if same room contact is expected within 14 days of vaccination or 7 days after booster, or prior to evidence of vaccine clearance * Immunodeficient household members or other close contacts if same room contact is expected within 14 days of vaccination or 7 days after booster, or prior to evidence of vaccine clearance * Current use of investigational or immunosuppressive drugs (e.g., steroids) * Current use of antibiotics or antivirals

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parainfluenza are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

parainfluenza infectious disease Paramyxoviridae infectious disease viral respiratory tract infection croup prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parainfluenza Respiratory viral infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.